Loading…

Vesiculobullous Eruption from Intense Pulsed Light Treatment

Background Intense pulsed light (IPL) systems emit noncoherent, polychromatic light and are increasingly used for various dermatologic indications. Although generally regarded as safe therapy, IPL is not without risk. Objective We report a 21‐year‐old woman who experienced a severe blistering erupti...

Full description

Saved in:
Bibliographic Details
Published in:Dermatologic surgery 2005-03, Vol.31 (3), p.345-349
Main Authors: Sperber, Brian R., Walling, Hobart W., Arpey, Christopher J., Whitaker, Duane C.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Intense pulsed light (IPL) systems emit noncoherent, polychromatic light and are increasingly used for various dermatologic indications. Although generally regarded as safe therapy, IPL is not without risk. Objective We report a 21‐year‐old woman who experienced a severe blistering eruption after IPL treatment by a nonphysician. Materials and Methods Case report. Results The patient reported a 10‐year history of persistent redness on her medial and lateral cheeks. She had tried no previous oral or topical therapies. She was diagnosed with rosacea and was treated with IPL. The following day, intense vesiculation and bullae formation occurred, progressing to dramatic facial edema by day 3 and eschar formation by day 5. Ten weeks later, prominent erythema with papularity remained on both cheeks and the lateral neck, with textural change and reticulated dyschromia. She continued to recover 20 weeks after treatment. Conclusion This case most likely represents high‐fluence photothermal tissue injury induced by the laser‐like qualities of the IPL source, with resulting acantholysis leading to formation of vesicobullae in the context of an uncertain primary diagnosis. This case highlights the potential hazards of IPL therapy and raises questions regarding appropriate use of this medical technology. BRIAN R. SPERBER, MD, PhD, HOBART W. WALLING, MD, PhD, CHRISTOPHER J. ARPEY, MD, AND DUANE C. WHITAKER, MD, HAVE INDICATED NO SIGNIFICANT INTEREST WITH COMMERCIAL SUPPORTERS.
ISSN:1076-0512
1524-4725
DOI:10.1111/j.1524-4725.2005.31085